374Water to Host Fourth Quarter and Full Year 2024 Results Conference Call on Thursday, March 27, 2025 at 4:30 p.m. Eastern Time DURHAM, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, after market close on Thursday, March 27, 2025. Following this, the Company will hold a conference call at 4:30 p.m. Eastern time to discuss i...
NewtekOne, Inc. Closes Private Offering of Senior Unsecured Notes NewtekOne’s Credit Rating Upgraded by Egan-Jones BOCA RATON, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) has completed an exempt offering of $30.0 million aggregate principal amount of its 8.375% notes due 2030 (the “Notes” and the "Offering"). The Offering was consummated pursuant to the terms of a purchase agreement (the “Purchase Agreement”) dated March 19, 2025 between the Company and eleven institutional accredited investors (the “Purchasers”). The Purchase Agreement provided for the Note...
374Water Announces its AirSCWO Technology is Successful in Eliminating LNAPL-Based PFAS from Impacted Groundwater Samples from the U.S. Navy Results Underscore the Robustness of AirSCWO Technology in Eliminating PFAS and Transforming Complex Waste Streams DURHAM, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today announced the successful treatment and destruction of Light Non-Aqueous Phase Liquid (LNAPL) impacted with Per- and Polyfl...
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growthClosed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in JanuaryAcquired and relaunched ultra rare disease product Galzin®Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company’s pediatric endocri...
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Human...
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to c...
Nuvectis Pharma to Participate in the 37th Annual Roth Conference FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California. Event37th Annual Roth ConferenceDateMarch 17, 2025Time2:30 PM Pa...
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced positive results from its bioequivalence study of ET-600, a proprietary, patente...
374Water Announces Appointment of Raj Melkote as Chief Technology Officer R&D and Engineering Executive to Drive Innovation and Growth DURHAM, N.C., March 13, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today announced the appointment of Raj Melkote as its new Chief Technology Officer (“CTO”). Raj Melkote brings over 30 years of experience as a Research & Development and Engineering executive with a track record of introducing and commercializing ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.